Page 29 - Read Online

Page 22 of 28 Cheng et al. Cancer Drug Resist. 2025;8:46

13. Suvac A, Ashton J, Bristow RG. Tumour hypoxia in driving genomic instability and tumour evolution. Nat Rev Cancer. 2025;25:167-88.
DOI PubMed
14. Cheng X, Li H, Ge X, et al. Tumor-microenvironment- responsive size-shrinkable drug-delivery nanosystems for deepened penetration
into tumors. Front Mol Biosci. 2020;7:576420. DOI PubMed PMC
15. Bhattarai D, Xu X, Lee K. Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): a “structure–activity
relationship” perspective. Med Res Rev. 2018;38:1404-42. DOI PubMed
16. Akanji MA, Rotimi D, Adeyemi OS. Hypoxia-inducible factors as an alternative source of treatment strategy for cancer. Oxid Med Cell
Longev. 2019;2019:8547846. DOI PubMed PMC
17. Yan Y, Li H, Yao H, Cheng X. Nanodelivery systems delivering hypoxia-inducible factor-1 alpha short interfering RNA and antisense
oligonucleotide for cancer treatment. Front Nanotechnol. 2022;4:932976. DOI
18. Hatanaka M, Shimba S, Sakaue M, et al. Hypoxia-inducible factor-3 alpha functions as an accelerator of 3T3-L1 adipose differentiation.
Biol Pharm Bull. 2009;32:1166-72. DOI PubMed
19. Mandl M, Lieberum M, Depping R. A HIF-1α-driven feed-forward loop augments HIF signalling in Hep3B cells by upregulation of
ARNT. Cell Death Dis. 2016;7:e2284. DOI PubMed PMC
20. Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med. 2016;94:613-27. DOI
PubMed PMC
21. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functions. Exp
Mol Med. 2004;36:1-12. DOI PubMed
22. Bharadwaj LA, Davies GF, Xavier IJ, Ovsenek N. l-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible
factor (HIF-1 α) in H9c2 cardiomyoblasts. Pharmacol Res. 2002;45:175-81. DOI PubMed
23. Appelhoff RJ, Tian Y, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of
hypoxia-inducible factor. J Biol Chem. 2004;279:38458-65. DOI PubMed
24. Berra E. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J.
2003;22:4082-90. DOI PubMed PMC
25. Chua YL, Dufour E, Dassa EP, et al. Stabilization of hypoxia-inducible factor-1α protein in hypoxia occurs independently of
mitochondrial reactive oxygen species production. J Biol Chem. 2010;285:31277-84. DOI PubMed PMC
26. Pereira T, Zheng X, Poellinger L. Degradation of the hypoxia-inducible factor 1α, where does it happen? Cell Cycle. 2006;5:2720-2.
DOI PubMed
27. Peng X, Gao H, Xu R, Wang H, Mei J, Liu C. The interplay between HIF-1α and noncoding RNAs in cancer. J Exp Clin Cancer Res.
2020;39:1535. DOI PubMed PMC
28. Kanno H, Matsumoto S, Yoshizumi T, et al. Role of SOCS and VHL proteins in neuronal differentiation and development. IJMS.
2023;24:3880. DOI PubMed PMC
29. Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. Cell Metab. 2018;27:281-98. DOI PubMed
30. Smolarz B, Łukasiewicz H, Samulak D, et al. Hypoxia-induced factor-1α and its role in endometrial cancer. Anticancer Res.
2024;44:3697-712. DOI PubMed
31. Seymour L, Nuru N, Johnson KR, et al. Roles of post-translational modifications of transcription factors involved in breast cancer
hypoxia. Molecules. 2025;30:645. DOI PubMed PMC
32. Zhao Z, Mu H, Li Y, Liu Y, Zou J, Zhu Y. Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a
meta-analysis including 5177 patients. Clin Transl Oncol. 2020;22:1892-906. DOI PubMed
33. Zhang C, Yang K, Yang G. Design strategies for enhancing antitumor efficacy through tumor microenvironment exploitation using
albumin-based nanosystems: a review. Int J Biol Macromol. 2024;258:129070. DOI PubMed
34. Yang M, Li J, Gu P, Fan X. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact
Mater. 2021;6:1973-87. DOI PubMed PMC
35. Liu J, Jiang Y, Chen L, Qian Z, Zhang Y. Associations between HIFs and tumor immune checkpoints: mechanism and therapy. Discov
Onc. 2024;15:836. DOI PubMed PMC
36. Famta P, Shah S, Vambhurkar G, et al. Amelioration of breast cancer therapies through normalization of tumor vessels and
microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation. Drug Deliv Transl Res. 2025;15:389-406. DOI
PubMed
37. Saha P, Ettel P, Weichhart T. Leveraging macrophage metabolism for anticancer therapy: opportunities and pitfalls. Trends Pharmacol
Sci. 2024;45:335-49. DOI PubMed
38. Yuan Q, Jia L, Yang J, Li W. The role of macrophages in liver metastasis: mechanisms and therapeutic prospects. Front Immunol.
2025;16:1542197. DOI PubMed PMC
22